A retrospective study assessing durvalumab in stage III unresectable non-small cell lung cancer (NSCLC) patients
Latest Information Update: 16 Oct 2019
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 16 Oct 2019 New trial record